Rosetta Genomics (ROSG) drifts back to unchanged following a 5% pop in the pre-market after it...

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Rosetta Genomics (ROSG) drifts back to unchanged following a 5% pop in the pre-market after it announced a settlement agreement with Sanra Laboratories on the previous sale of Parkway Clinical Laboratories. Under the terms of the settlement, Sanra agrees to make a "best effort" to pay ROSG $625K, in addition to all sums previously paid by them according to the stock purchase agreement entered into in May 2009.